Corpus overview


Overview

MeSH Disease

Human Phenotype

Tachycardia (4)

Pneumonia (2)

Pain (2)

Fever (2)

Hypoxemia (1)


Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    EPICOVID19: Psychometric assessment and validation of a short diagnostic scale for a rapid Covid-19 screening based on reported symptoms

    Authors: Luca Bastiani; Loredana Fortunato; Stefania Pieroni; Fabrizio Bianchi; Fulvio Adorni; Federica Prinelli; Andrea Giacomelli; Gabriele Pagani; Stefania Maggi; Caterina Trevisan; Marianna Noale; Nithiya Jesuthasan; Aleksandra Sojic; Carla Pettenati; Massimo Andreoni; Raffaele Antonelli Incalzi; Massimo Galli; Sabrina Molinaro

    doi:10.1101/2020.07.22.20159590 Date: 2020-07-25 Source: medRxiv

    Background Confirmed COVID-19 cases have been reported in 213 countries and regions and as of 12 July 2020, over 12 million cases, with 561617 deaths MESHD have been reported worldwide. The number of cases changes quickly and varies depending upon which source you use to track, so in the current epidemiological context, the early recognition is critical for the rapid identification of suspected cases (with SARS-CoV-2 infection MESHD-like symptoms and signs MESHD) to be immediately subjected to quarantine measures. Although surveys are widely used for identifying COVID-19 cases, outcomes and associated risks, no validated epidemiological tool exists for surveying SARS-CoV-2 infection MESHD in the population so far. Methods Our study is the phase II of the EPICOVID19 national survey, launched in April 2020 including a national convenience sample of 201121 adults TRANS, who voluntarily filled the EPICOVID19 questionnaire. The phase II questionnaire was mailed to all subjects who underwent tests for COVID-19 by nasopharyngeal swab (NPS) and who accepted to be involved in the second phase of the study, focused on the results reported for NPS and/or serological IgG/IgM tests. We evaluated the capability of the self-reported symptoms collected through the EPICOVID19 questionnaire to discriminate the COVID-19 among symptomatic subjects, in order to identify possible cases to undergo instrumental measurements and clinical examinations. We defined a method for the identification of a total score and validated it with reference to the serological and molecular clinical diagnosis, using four standard steps: identification of critical factors, confirmation of presence of latent variable, development of optimal scoring algorithm and validation of the scoring algorithm. Findings 2703 subjects [66% response rate] completed the Phase II questionnaire. Of 2703 individuals, 694 (25.7%) were NPS(+) and of these 84 (12.1% of the 694 NPS(+)) were asymptomatic TRANS. In the individuals who performed serological testing SERO, of the 472 who did IgG(+) and 421 who did IgM(+), 22.9% and 11.6% tested positive, respectively. Among IgG(+) 1 of 108 subjects was asymptomatic TRANS (0.9%) while 5/49 subjects among IgM(+) were asymptomatic TRANS (10.2%). Compared with NPS(-), among NPS(+) subjects there was a higher rate for Fever MESHD Fever HP (421 [60.7%] vs 391[19.5% ]; p<0.0001), Loss of Taste and/or Smell (365 [52.6%] vs 239 [11.9% ]; p<0.0001) and Cough MESHD Cough HP (352 [50.7%] vs 580 [28.9% ]; p<0.0001). Also for other symptoms the frequencies were significantly higher in NPS(+) subjects than in NPS(-) ones (p<0.001). Among groups with serological tests SERO, the symptoms with higher percentages in the subjects IgG(+) were Fever MESHD Fever HP (65 [60.2%] vs 43[11.8% ]; p<0.0001) and Pain MESHD Pain HP in muscles, bones, joints (73 [67.6%] vs 71 [19.5% ]; p<0.0001). For the COVID-19 self-reported symptoms items, exploratory (proportion variance explained [89.9%]) and confirmatory factor analysis results (SMSR 0.072; RMSEA 0.052) highlights the presence of one latent variable (factor) underlying the symptoms. We define the one-factor solution as EPICOVID19 diagnostic scale and optimal score for each items was identified: Respiratory problems (1.03), Chest pain MESHD Chest pain HP (1.07), Loss of Taste and/or Smell (0.97) and Tachycardia MESHD Tachycardia HP ( palpitations HP) (1.05) were the most important symptoms. The cut-off score was 2.56 ( Sensitivity SERO 76.56%; Specificity 68.24%) in NPS(+) and 2.59 (Se 80.37; Sp 80.17) in IgG(+) subjects.

    Syncope MESHD Syncope HP at SARS-CoV-2 onset due to impaired baroreflex response

    Authors: Ciro Canetta; Silvia Accordino; Elisabetta Buscarini; Gianpaolo Benelli; Giuseppe La Piana; Alessandro Scartabellati; Giovanni Vigano'; Roberto Assandri; Alberto Astengo; Chiara Benzoni; Gianfranco Gaudiano; Daniele Cazzato; Sebastiano Davide Rossi; Susanna Usai; Irene Tramacere; Giuseppe Lauria

    doi:10.1101/2020.05.29.20114751 Date: 2020-06-02 Source: medRxiv

    We describe clinical and laboratory findings in 35 consecutive patients tested positive for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction on nasopharyngeal swab that presented one or multiple syncopal events at disease MESHD onset. Neurological examination and electrocardiographic findings were normal. Chest computed tomography showed findings consistent with interstitial pneumonia MESHD pneumonia HP. Arterial blood SERO gas analysis showed low pO2, pCO2, and P/F ratio indicating hypocapnic hypoxemia HP, while patients did not show the expected compensatory heart rate increase. Such mechanism could have led to syncope MESHD syncope HP. We speculate that SARS-CoV-2 could have caused angiotensin-converting enzyme-2 (ACE2) receptor internalization in the nucleus of the solitary tract (NTS), thus altering the baroreflex response and inhibiting the compensatory tachycardia MESHD tachycardia HP during acute hypocapnic hypoxemia HP.

    Covid-19 infection MESHD without respiratory symptoms: case report of diagnosing a 14 year-old patient with acute abdomen 

    Authors: Ladan Goshayeshi; Nasrin Milani; Robert Bergqueist; Sayyed Majid Sadrzadeh; Farnood Rajabzadeh; Benyamin Hoseini

    doi:10.21203/rs.3.rs-27389/v1 Date: 2020-05-07 Source: ResearchSquare

    Background. Coronavirus Disease MESHD 2019 (Covid-19) is expanding worldwide. Although it seems to be a purely respiratory disease MESHD, occasional reports of lesions in other organs have been published. We report here an asymptomatic TRANS child TRANS Covid-19 patient with the main symptom of abdominal HP abdominal pain MESHD pain HP distension and without any respiratory symptoms.Case presentation. A 14 year-old male TRANS patient without respiratory involvement but with main complaints of fever MESHD fever HP, malaise, anorexia MESHD anorexia HP, and severe abdominal pain MESHD abdominal pain HP was admitted to a hospital in Mashhad, Iran. Following general anaesthesia, laparotomy revealed distension of the small intestine and an adhesive ileo-caecal band that had produced ileum herniation without free fluid in the abdomen. The band was surgically severed and the patient referred to the recovery room.  Because of pulse rate of 36-40 per min and respiratory rate of 140 and a saturated O2 of 86%, the patient was referred to the intensive care unit. Chest X-ray and high-resolution computed tomography of the lungs showed bilateral, diffuse, peripheral dense areas of ground-glass appearance. A nasopharyngeal swab for Covid-19 diagnosis, ordered due to lymphopenia MESHD lymphopenia HP together with these diffuse lung infiltrations, showed a positive result. This led to drug treatment with lopinavir/ritonavir, hydroxychloroquine, ribavirin/oseltamivir and meropenem. The patient was febrile and developed tachycardia MESHD tachycardia HP on the third day accompanied with a respiratory rate of 44/min. At this point, tracheal intubation was done but the patient died after 3 hours due to cardiac arrest HP.Conclusions. The case report brings forth the hypothesis that the gastrointestinal manifestation may be untypical symptoms of Covid-19 infection MESHD, and highlights the importance for the diagnosis to be based on combined laboratory-based data and scanning imagery.

    Acute Myocardial Injury of Patients with Coronavirus Disease MESHD 2019

    Authors: Huayan Xu; Keke Hou; Hong Xu; Zhenlin Li; Huizhu Chen; Na Zhang; Rong Xu; Hang Fu; Ran Sun; Lingyi Wen; Linjun Xie; Hui Liu; Kun Zhang; Joseph B Selvanayagam; Chuan Fu; Shihua Zhao; Zhigang Yang; Ming Yang; Yingkun Guo

    doi:10.1101/2020.03.05.20031591 Date: 2020-03-08 Source: medRxiv

    Background: Since the outbreak of the Coronavirus Disease MESHD 2019 (COVID-19) in China, respiratory manifestations of the disease MESHD have been observed. However, as a fatal comorbidity, acute myocardial injury (AMI) in COVID-19 patients has not been previously investigated in detail. We investigated the clinical characteristics of COVID-19 patients with AMI and determined the risk factors for AMI in them. Methods: We analyzed data from 53 consecutive laboratory-confirmed and hospitalized COVID-19 patients (28 men, 25 women; age TRANS, 19-81 years). We collected information on epidemiological and demographic characteristics, clinical features, routine laboratory tests (including cardiac injury biomarkers), echocardiography, electrocardiography, imaging findings, management methods, and clinical outcomes. Results: Cardiac complications were found in 42 of the 53 (79.25%) patients: tachycardia MESHD tachycardia HP (n=15), electrocardiography abnormities (n=11), diastolic dysfunction (n=20), elevated myocardial enzymes (n=30), and AMI (n=6). All the six AMI patients were aged TRANS >60 years; five of them had two or more underlying comorbidities ( hypertension MESHD hypertension HP, diabetes, cardiovascular diseases MESHD diseases, and chronic obstructive pulmonary HP chronic obstructive pulmonary disease MESHD). Novel coronavirus pneumonia MESHD pneumonia HP (NCP) severity was higher in the AMI patients than in patients with non-definite AMI (p<0.001). All the AMI patients required care in intensive care unit; of them, three died, two remain hospitalized. Multivariate analyses showed that C-reactive protein (CRP) levels, NCP severity, and underlying comorbidities were the risk factors for cardiac abnormalities in COVID-19 patients. Conclusions: Cardiac complications are common in COVID-19 patients. Elevated CRP levels, underlying comorbidities, and NCP severity are the main risk factors for cardiac complications in COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.